Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..10 of 31 - per page Next page
Order by
Antroquinonol® is a non-toxic, highly effective cancer treatment agent, developed using natural organic chemistry. More
Patented technology regarding new and safe mechanism with the active substance PH3 for the indications of osteoporosis and diabetic vascular complications. More
High yield and low cost protein production in a few days to a couple of weeks (mg or g of protein). Production of proteins, including antibodies, for High-throughput screening assays, antibody generation and structure-activity analyses. More
A number of specific PPLs, a group of prenylflavanone compounds, some novel, were isolated, identified and tested at as low as 0.04 μg/mL to be able to increase survival of neural stem cells, to promote neuronal growth with lengthening of neurite More
Technology regarding new methods to efficiently and cost-effectively produce recombinant proteins from the milk of genetically-modified farm animals, applying methodologies of genetic engineering and transgenesis to pharmaceutical manufacturing. More
Compositions and methods for improving the growth characteristics of cells engineered to produce biologically active products such as antibodies or glycosylated proteins. More
A new technology to address several current stumbling blocks in animal cloning. This technology dramatically enhances the probability of producing normal offspring that are truly genetically identical. More
Novel target and monoclonal antibody for early diagnosis and/or therapeutic intervention More
The cumate-inducible expression system allows turning on the expression of a given protein only when needed. More
Researchers from the University of Edinburgh have generated a MBD3-deficient pluripotent embryonic stem cell line. More
Displaying 1..10 of 31 - per page Next page
Order by
Partnering consultation free of charge
Need competitive intelligence information
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us